Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Gilead’s science is only half the battle—decoding its SEC paperwork is the other. Each 10-K can exceed 250 pages of antiviral sales data, oncology trial risk factors, and patent-expiry timelines that impact Biktarvy’s future cash flows. Add surprise 8-K material events on FDA outcomes and dozens of Form 4 insider trades from researchers at Kite Pharma, and the disclosure maze grows fast.
Stock Titan’s AI resolves that complexity. Our platform streams every Gilead Sciences SEC filing the moment it hits EDGAR and delivers plain-English summaries that pinpoint what matters: a spike in R&D spend called out in the latest "Gilead Sciences quarterly earnings report 10-Q filing," a newly granted patent buried in an exhibit, or fresh "Gilead Sciences insider trading Form 4 transactions" that hint at management’s sentiment. Interactive highlights explain cash-flow sensitivities, collaboration milestones, and CAR-T manufacturing risks so you understand "Gilead Sciences SEC filings explained simply" instead of parsing dense legal text.
Use cases include:
- Setting real-time alerts for "Gilead Sciences Form 4 insider transactions" before pivotal trial readouts.
- Comparing segment revenue across HIV, hepatitis C, and oncology lines straight from 10-Q tables.
- Reviewing "Gilead Sciences proxy statement executive compensation" to evaluate R&D incentive alignment.
- Scanning "Gilead Sciences 8-K material events explained" for FDA complete-response letters.
- Reading a "Gilead Sciences annual report 10-K simplified" summary that flags looming patent cliffs.
Whether you’re modelling drug royalties, monitoring "Gilead Sciences executive stock transactions Form 4," or just learning "understanding Gilead Sciences SEC documents with AI," our coverage gives you every filing—and the context—to make informed decisions in minutes, not hours.
Gilead Sciences announced its financial results for the quarter ended September 30, 2025 and furnished a press release as Exhibit 99.1.
The company presented GAAP and non-GAAP measures, with reconciliations provided in the press release tables. The information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference.
Gilead Sciences (GILD) insider filing: Chairman & CEO Daniel P. O’Day reported open‑market sales totaling 10,000 shares on 10/28/2025 under a Rule 10b5‑1 trading plan adopted on February 28, 2025. The transactions were coded “S”.
He sold 7,978 shares at an average price of $119.5371 and 2,022 shares at $118.8223. Following the sales, he beneficially owns 581,203 shares directly, down from 583,225 before these trades. The filing notes price ranges for each trade, with full breakdowns available upon request to the company, the SEC, or shareowners.
Gilead Sciences (GILD): Officer equity transaction reported
On 10/25/2025, an officer of Gilead Sciences (title: EVP, Corporate Affairs & GC) reported the conversion of 515 restricted stock units into common stock (transaction code M) and the disposition of 241 shares at $120.94 (transaction code F). Following these transactions, the officer directly owned 43,676 shares of common stock.
The filing also shows 19,816 restricted stock units beneficially owned after the reported transaction. The RSUs vest over four years: 25% on the first anniversary of grant, then 6.25% quarterly until fully vested.
Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.
Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.
Gilead Sciences (GILD) disclosed an insider transaction by Chief Commercial Officer Johanna Mercier. On 10/15/2025, she sold 3,000 shares of common stock at $118.08 per share (transaction code S). After the sale, she beneficially owned 110,193 shares, held directly.
The filing states the trade was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Daniel P. O'Day, Chairman & CEO of Gilead Sciences (GILD), reported sales of common stock on 09/29/2025 under a pre-established Rule 10b5-1 trading plan adopted February 28, 2025. The Form 4 shows two sale transactions: 8,039 shares sold at prices reported in a range around $110.97–$111.92 and 1,961 shares sold at prices reported in a range around $112.00–$112.55. After these transactions the reporting person beneficially owned 591,203 shares. The filing was submitted under Section 16 and executed by power of attorney. The disclosure states that full per-price breakdowns are available on request.
Form 144 filing by an insider of Gilead Sciences (GILD) reporting proposed and recent sales of common stock. The notice shows a proposed sale of 10,000 shares to be executed through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $1,116,564.00. The shares were originally acquired as restricted stock on 03/01/2020. The filing also discloses three completed sales by the same person, DANIEL O'DAY, of 10,000 shares each on 06/30/2025, 07/28/2025, and 08/28/2025 for gross proceeds of $1,104,483.00, $1,139,369.00, and $1,136,300.00, respectively. The filing lists 1,240,806,916 shares outstanding for the class and identifies NASDAQ as the exchange.
Erin Burkhart, SVP, Controllership at Gilead Sciences (GILD), was granted 8,890 restricted stock units (RSUs) on 09/22/2025. Each RSU represents the contingent right to receive one share of common stock. The RSUs follow a four-year vesting schedule: 25% vests on the first anniversary of the grant date, with the remainder vesting at 6.25% each quarter thereafter until fully vested. Following the reported grant, Ms. Burkhart beneficially owns 8,890 shares subject to vesting, held directly. The Form 4 was filed by one reporting person and signed under power of attorney on 09/23/2025.
Erin E. Burkhart, identified as Senior Vice President, Controllership, filed an Initial Statement on Form 3 reporting her relationship to Gilead Sciences, Inc. (GILD). The event date requiring the statement is 09/22/2025. The filing discloses that no securities are beneficially owned by the reporting person as of the filing. The form indicates it was signed on behalf of Ms. Burkhart by Edward S. Son under power of attorney on 09/23/2025. This is a routine Section 16 initial disclosure showing officer status and no current ownership in the issuer.
FAQ
What is the current stock price of Gilead Sciences (GILD)?
What is the market cap of Gilead Sciences (GILD)?
